AI stocks rebound, and why J&J’s earnings guidance cut is not cause for concern
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
Novo Nordisk sued by shareholders over weight-loss drug: What to know
A federal judge on Tuesday allowed parts of that lawsuit to move forward, finding that investors had plausibly…
Novo Nordisk looks to block Eli Lilly weight-loss drug ads
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters Novo Nordisk said on…
FDA is urged by advocacy group to ban DTC prescription drug ads
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
Eli Lilly will file for approval of retatrutide obesity drug in 2027
The Eli Lilly logo appears on the company’s office in San Diego, California, Nov. 21, 2025. Mike Blake…
Barriers may keep Merck’s new cholesterol drug from success
A long-awaited moment in preventive cardiology arrived last week, when enlicitide (which Merck is selling under the name…
Rare disease drugmakers seek exclusion from Medicare pricing plans
WASHINGTON — Biotech companies are lobbying the Trump administration to exclude treatments for rare diseases from programs that…
Singapore bets on AI in healthcare, but success will depend on commercial sustainability
Private sector needs to translate AI productivity gains into cost savings for patients, experts say [SINGAPORE] Artificial intelligence…
Novo Nordisk sues Eli Lilly over GLP-1 ads
Photo illustration of a group of weight loss medications on a white background. Ucg | Universal Images Group…
What to know about testosterone replacement therapy
US Secretary of Defense Pete Hegseth speaks during a press briefing at the Pentagon in Washington, DC, on…
Daily polypill significantly improves cardiac function in heart failure patients
Treatment with a “polypill” that combines multiple medications into a single daily dose significantly enhanced cardiac function and reduced…
Access to potential long COVID drugs dwindles as trials falter
Key Insights Drug manufacturers have quietly discontinued trials in long COVID and related illnesses, leaving patients in…